UPDATE: Canaccord Genuity Raises PT to $10 on Synergy Pharmaceuticals on Positive Plecanatide Data
Canaccord Genuity reiterated its Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) and increased its price target from $7 to $10.
Canaccord Genuity noted, "Reiterate BUY, raise target to $10 on increased probability of success for plecanatide in CIC. We see clear unmet need in chronic constipation (CIC) patients who don't respond/have AEs on current therapies. Compared to Linzess (FRX/IRWD), plecanatide may have better tolerability (no diarrhea in Phase 2a). We are raising our pNPV based target to $10 from $7, driven by increased chance of plecanatide success on today's positive proof of concept data."
Synergy Pharmaceuticals closed at $5.26 on Monday.
Latest Ratings for SGYP
|Aug 2015||BTIG Research||Initiates Coverage on||Buy|
|Jun 2015||Canaccord Genuity||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.